Antidiarrheal Drugs Market Set for Remarkable Growth, To Grow at a Lucarative CAGR – Zion Market Research
Diarrhea is characterized by loose, watery stools or a recurrent need to have a bowel movement; it usually lasts a few days and often dissipates without any treatment. Diarrhea can be acute or chronic in nature. Antidiarrheal drugs are used to treat abrupt diarrhea and possess the mechanism of slowing down the movement of the gut and helps to diminish the number of bowel movements and also make the stools less watery. Distinct causes of diarrhea can be a virus such as a rotavirus, hepatitis, a bacterium such as E.coli, Shigella, and parasites causing amoebiasis and giardiasis. Majority of the events of diarrhea are recognized to be concluded with simple dietary modifications and may not require treatment, however, in certain cases of severe diarrhea, laboratory assessment is requisite which includes blood tests, and stool specimen evaluation to analyze the type of diarrhea. The global antidiarrheal drugs market is flourishing at a substantial pace owing to increasing incidences of diarrhea and increasing awareness.
Global Antidiarrheal Drugs Market: Growth Factors
Multiple factors are driving the growth of the global antidiarrheal market such as rising consciousness towards antidiarrheal drugs, increasing government initiatives for development in healthcare facilities and increasing prevalence of diarrhea. Influx of antidiarrheal drugs for HIV/AIDS such as Fulyzaq (crofelemer) by Glenmark Pharmaceuticals is anticipated to drive the growth of the global antidiarrheal drugs market during the forecast period. However, numerous side effects associated with antidiarrheal drugs, essentially constipation, fullness and bloating, nausea or vomiting and dizziness are the restraining factors in the growth of the global antidiarrheal drugs market. Furthermore, classical and home remedies are still prominent in developing countries and are expected to hamper the growth of the global antidiarrheal market over the forecast period.
Get Sample of this Research Report – https://www.zionmarketresearch.com/sample/antidiarrheal-drugs-market
Global Antidiarrheal Drugs Market: Segmentation
The global antidiarrheal drugs market is segmented on the basis of type, drug class, and application. Based on type – OTC drugs and prescription drugs; based on drug class – mucosal protectants and absorbents such as kaolin-pectin & activated charcoal, motility modifying drugs such as anticholinergics and opiates, antimicrobial therapy, non-steroidal anti-inflammatory drugs and anti-toxins; based on application – adults and children.
Global Antidiarrheal Drugs Market: Regional Analysis
North America is the leading market in the global antidiarrheal drugs market and is expected to attain a commanding position during the forecast period. Acute diarrhea is one of the most regularly reported illness in the U.S., according to the WHO, diarrhea is the second leading cause of death, especially in children under 5 years of age. High prevalence of diarrhea and higher adoption rate for antidiarrheal drugs are the driving forces expected to fuel the antidiarrheal drugs market in the region during the forecast period. Furthermore, Asia-Pacific is expected to experience rapid growth during the forecast period, wherein emerging economies such as China and India are the key consumers of antidiarrheal drugs owing to unhygienic and improper sanitation procedures, increasing awareness and infrastructure.
Global Antidiarrheal Drugs Market: Competitive Players
Some of the key players in the global antidiarrheal market are Johnson & Johnson, Novartis, GlaxoSmithKline, Proctor & Gamble, Pfizer, Actelion, Perrigo, Lupin, Glenmark Pharmaceuticals, Sanofi Aventis, Merck & Co., and Bayer
- CDN Newswire